Optimizing Exchange Transfusion for Severe Unconjugated Hyperbilirubinemia:Studies in the Gunn Rat by Schreuder, Andrea B. et al.
  
 University of Groningen
Optimizing Exchange Transfusion for Severe Unconjugated Hyperbilirubinemia
Schreuder, Andrea B.; Vanikova, Jana; Vitek, Libor; Havinga, Rick; Ahlfors, Charles E.;





IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2013
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Schreuder, A. B., Vanikova, J., Vitek, L., Havinga, R., Ahlfors, C. E., Hulzebos, C. V., & Verkade, H. J.
(2013). Optimizing Exchange Transfusion for Severe Unconjugated Hyperbilirubinemia: Studies in the
Gunn Rat. PLoS ONE, 8(10), [e77179]. https://doi.org/10.1371/journal.pone.0077179
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
Optimizing Exchange Transfusion for Severe
Unconjugated Hyperbilirubinemia: Studies in
the Gunn Rat
Andrea B. Schreuder1, Jana Vanikova2, Libor Vitek2,3, Rick Havinga1, Charles E. Ahlfors4,
Christian V. Hulzebos5, Henkjan J. Verkade1*
1 Pediatric Gastroenterology and Hepatology, Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, Beatrix Children’s Hospital - University Medical
Center Groningen, University of Groningen, Groningen, The Netherlands, 2 Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Faculty of Medicine, Charles
University, Prague 2, Czech Republic, 3 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague 2, Czech Republic, 4 Stanford University,
School of Medicine, Stanford, California, United States of America, 5Neonatology, Department of Pediatrics, Beatrix Children’s Hospital - University Medical Center
Groningen, Groningen, The Netherlands
Abstract
Background: Severe unconjugated hyperbilirubinemia carries the risk of neurotoxicity. Phototherapy (PT) and exchange
transfusion (ET) are cornerstones in the treatment of unconjugated hyperbilirubinemia. Studies to improve ET efficacy have
been hampered by the low application of ET in humans and by the lack of an in vivo model. The absence of an appropriate
animal model has also prevented to determine the efficacy of adjunct or alternative treatment options such as albumin (Alb)
administration.
Aim: To establish an in vivo model for ET and to determine the most effective treatment (combination) of ET, PT and Alb
administration.
Methods: Gunn rats received either PT, PT+Alb, ET, ET+PT, ET+PT+Alb or sham operation (each n= 7). ET was performed via
the right jugular vein in ,20 min. PT (18 mW/cm2/nm) was started after ET or at T0. Albumin i.p. injections (2.5 g/kg) were
given after ET or before starting PT. Plasma unconjugated bilirubin (UCB), plasma free bilirubin (Bf), and brain bilirubin
concentrations were determined.
Results: We performed ET in 21 Gunn rats with 100% survival. At T1, ET was profoundly more effective in decreasing both
UCB244%, p,0.01) and Bf281%, p,0.05) than either PT or PT+Alb. After 48 h, the combination of ET+PT+Alb showed the
strongest hypobilirubinemic effect (254% compared to ET).
Conclusions:We optimized ET for severe unconjugated hyperbilirubinemia in the Gunn rat model. Our data indicate that ET
is the most effective treatment option, in the acute as well as the follow-up situation.
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Introduction
Neonatal jaundice carries the risk of neurotoxicity, due to the
deposition of unconjugated bilirubin (UCB) in the central nervous
system. Most of the UCB (,99%) in plasma is bound to plasma
proteins (mainly albumin). Only a small fraction (,1%) is ‘‘free’’,
and only this free bilirubin (Bf) has the ability to cross the blood-
brain barrier and to induce brain damage [1–5].
Presently, the standard treatment for hyperbilirubinemia is
phototherapy. Phototherapy (PT) is generally effective, but in
some neonates the plasma bilirubin concentrations become
dangerously high or rise rapidly despite PT. In these patients PT
might fail to prevent bilirubin-induced brain damage, and for
these patients exchange transfusion (ET) is indicated. Exchange
transfusions have more serious side effects and complications than
PT. The mortality rate from the procedure is approximately 0.3–
2.0%. Significant morbidity is associated with 5–12% of ETs [6–
8]. Complications include cardiac arrest, thrombosis of the portal
vein, graft vs. host disease, coagulopathies, hypoglycemia,
hypocalcaemia, necrotizing enterocolitis, and transmission of
infectious diseases [6–10].
It has remained unclear whether ET could successfully be
replaced by other, more effective treatment options. For example,
albumin infusion might be a good treatment modality. Recently,
we found that adjunct human serum albumin (HSA) increased the
efficacy of PT; it decreased plasma Bf concentrations and brain
bilirubin levels by ,90% and ,70%, respectively [11]. Studies to
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replace ET, to improve ET efficacy and/or to minimize its risks
have been hampered by the contemporary low application rate of
ET in humans and by the lack of an appropriate in vivo model
system. In order to better study the effects of an ET, animal studies
would be highly desirable. An appropriate animal model should
resemble the human situation as much as possible. In case of ET
for hyperbilirubinemia, it should lower the bilirubin levels
sufficiently, quickly and safely. In this study we set out to establish
an animal model for ET, in which we would be able to evaluate
the effect of an ET on bilirubin concentrations in the acute and
long-term situation.
We used Gunn rats suffering from hyperbilirubinemia due to a
mutation in uridine diphosphoglucuronosyltransferase: UGT1A1
[12–15]. The Gunn rat is a well-established animal model for
unconjugated hyperbilirubinemia. The histopathological lesions in
severely kernicteric Gunn rats include damage to central auditory
structures, especially the cochlear nuclei and inferior colliculi, and
are similar to those found in human neonates with classic
kernicterus [16].
In the present study, we successfully optimized and verified an
ET model in Gunn rats to compare acute treatments for severe
hyperbilirubinemia. Next, we evaluated different acute treatment
options for hyperbilirubinemia with or without the combination of
ET, and compared total serum bilirubin, free bilirubin and brain
bilirubin levels.
Animals, Materials, and Methods
Animals
Homozygous male Gunn rats (RHA/jj; 10–12 weeks of age,
bodyweight: 254–335 g) from our breeding colony were kept in an
environmentally controlled facility, were fed ad libitum and had
free access to water. The Animal Ethics Committee of the
University of Groningen (Groningen, The Netherlands) approved
all experimental protocols.
Materials
Diet. Hope Farms B.V. (Woerden, The Netherlands) pro-
duced the semi-synthetic control diet (code 4063.02). This diet
contained 13 energy% fat and 5.2 wt% long-chain fatty acids.
Gunn rats were fed this diet during a 5-week run-in period, and
during the experimental period.
Chemicals. Horseradish peroxidase type 1, D-glucose, glu-
cose oxidase, and hydrogen peroxide were purchased from Sigma
Chemical Co. (St. Louis, MO). Human serum albumin (Albu-
manH; 200 g/L, fatty acid free) was purchased from Sanquin
(Amsterdam, The Netherlands).
Methods
Phototherapy. Two phototherapy devices were developed
according to the prototype that was designed by Ostrow et al. and
previously successfully used [11,17]. Each device consisted of two
blue phototherapy lamps (Philips, TL-20W/52) suspended in a
reflective canopy 30 cm above the bottom of the cage.
Phototherapy (18 mW/cm2/nm; 380–480 nm; measured by an
Elvos-LM-1010 Lux meter at 30 cm distance), was administered
continuously to Gunn rats, shaven on their backs and flanks.
Exchange transfusion. Fresh whole rat Wistar donor blood
was obtained from Harlan Laboratories B.V. (Horst, The
Netherlands). Exchange transfusion was carried out under general
anesthesia with isoflurane. Body temperature was maintained at
37–38uC by a heating plate. Saturation was checked and kept
constant during the whole procedure above 95%. Different vessel
approaches, including femoral artery and vein, the carotic artery
and jugular vein, have been tested and the following description
was used for all experiments. A small incision was made in the
right throat region and, with the aid of an operating microscope,
the right jugular vein was cannulated with heparinized silastic
tubing for the infusion of donor blood, and the extraction of the
native blood. In total 20 ml of donor blood was infused via a
heparinized lock, and 20 ml of native blood was taken out (1 ml
per cycle in 1 minute). Exchange transfusion was performed at a
rate of 1 ml/min, for 20 minutes. Blood outflow was performed by
hand using 1 ml syringes, and donor blood inflow was performed
using an infusion pump. After the exchange transfusion tubes were
ligated and left in situ, and the skin was sutured.
Sham transfusion. Sham transfusion was carried out
following the same procedure as the exchange transfusion. After
cannulation of the jugular vein, animals were kept under general
anesthesia for 20 minutes. After the sham the heparinized silastic
tubings were ligated extra corporally and the proximal part was
left in the jugular vein in situ. Finally, the skin was sutured.
Study Design
Adult Gunn rats were randomized to receive either sham
operation without treatment (controls), phototherapy, photother-
apy+HSA, an exchange transfusion, an exchange transfusion+-
phototherapy or an exchange transfusion+HSA+phototherapy
(each of these groups n= 7). The exchange transfusion (ET) group
underwent ET at a rate of 1 ml/min for 20 minutes. HSA i.p.
injection (2.5 g/kg) was given immediately after the ET or right
before PT was started. Heparinized samples of tail vein blood were
collected, under isoflurane anesthesia, at time (t) = 0 (before the
ET), at t = 1, t = 3, t = 6, and t = 24 h after the ET. After 48 h, all
animals were exsanguinated via the descending aorta and flushed
via the same port with 100–150 ml NaCl 0.9% under isoflurane
anesthesia. Brains were subsequently collected for the determina-
tion of tissue bilirubin levels. These samples were rinsed twice with
phosphate buffered saline, snap frozen in liquid nitrogen, and
immediately stored (wrapped in aluminum foil) at 280uC until
analysis.
Analytical Methods
Plasma analysis. Blood samples were protected from light,
stored at 220uC under argon directly after collection and
processed within 2 weeks. UCB and Bf were determined using a
Zone Fluidics system (Global Flopro, Global Fia Inc, WA), as
previously described by Ahlfors et al. [18].
Tissue bilirubin analysis. Tissue bilirubin content was
determined using HPLC with diode array detector (Agilent, Santa
Clara, CA) as described earlier [19]. Briefly, 300 pmol of
mesobilirubin in DMSO (used as an internal standard) was added
and samples were homogenized with glass dust using glass rod.
Bile pigments were then extracted into chloroform/methanol/
hexane (10:5:1) solution at pH 6.0, and subsequently extracted in
a minimum volume of methanol/carbonate buffer (pH 10) to
remove contaminants. The resulting polar droplet (extract) was
loaded onto C-8 reverse phase column (Phenomenex, Torrance,
CA) and separated pigments were detected at 440 nm. The
concentration of bilirubin was calculated as nmol/g of wet tissue
weight. All steps were performed under dim light in aluminum-
wrapped tubes. We did not specifically measure bilirubin
deposition in the brain nuclei, but relied on total tissue bilirubin
measurements.
Statistical analysis. Normally distributed data that dis-
played homogeneity of variance (by calculation of Levene’s
statistic) were expressed as mean 6 SD, and analyzed with
parametric statistical tests. Analysis of variance (ANOVA) with
A Rat Model for Exchange Transfusion
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post-hoc Tukey correction was performed for comparisons
between groups, and the Student t test for comparison of paired
data within groups. The level of significance was set at p,0.05.
Analyses were performed using SPSS Statistics 20.0 for Windows
(SPSS Inc., Chicago, IL).
Results
Development and Validation of the Model
In the human situation the common route for ET involves
catheterization of the umbilical vein, and arteriovenous or
venovenous exchange. Initially, we set out to establish arteriove-
nous exchange via the femoral artery and vein. Based on the
anatomical location, the femoral artery was not suitable for
exchange procedure. We then switched first to arteriovenous
exchange via the carotid artery and jugular vein, but this method
failed because of the high pressure in the carotid artery, which
made it impossible to keep the cannula in place for more than 5
minutes. Finally, we moved on to venovenous exchange via the
jugular vein on both sides. When we found out that we received
the same results in decrease of plasma bilirubin concentrations via
the push-and-pull-method via one jugular vein, as via the
continuous exchange via both jugular veins, we decided to
continue with the venovenous exchange via one jugular vein.
The rats recovered quickly with this method. Via the same jugular
vein we infused fresh Wistar donor blood (UCB ,1 mg/dL), and
extracted the blood of the Gunn rat, in 20 minutes. We tested
different lengths of the procedure and observed that 20 minutes
procedure led to the same decrease of plasma UCB concentrations
as 40 and 60 minutes procedures (same volume, data not shown).
We performed an ET in 21 Gunn rats with 100% survival. The
recovery after ET was rapid, illustrated by maintenance of body
weight during the 48 h after ET (at T48, 10063% compared to
T0, NS). Figure 1A shows the course of plasma UCB concentra-
tions after ET. ET rapidly decreased plasma UCB concentrations
from 14.9 mg/dL at T0, to 8.3 mg/dL at T1 (244%, p,0.001). In
Figure 1B the course of plasma Bf concentrations after ET is
shown. ET decreased plasma Bf concentrations from 11.1 mg/dL
at T0, to 2.1 mg/dL at T1 (281%, p,0.001). At T6, T24 and T48
no significant difference exist in plasma Bf concentrations between
controls and ET.
Plasma UCB Concentrations after 1 h
We compared the acute effect of the different treatments; PT,
ET, Alb administration or a combination thereof (Figure 2A).
After 1 h, PT showed no significant differences in plasma UCB
concentrations compared to controls. PT+Alb showed a significant
increase compared to controls (p,0.001). In contrast, ET reduced
plasma UCB concentrations by 47% within 1 h (p,0.001 vs
controls). The addition of either PT or the combination of PT and
Alb did not significantly augment this hypobilirubinemic effect.
Each of the combination therapies that included ET resulted in a
significantly lower plasma UCB concentration compared to the
control, PT or PT+Alb groups (each p,0.001).
Plasma Bf Concentrations after 1 h
Figure 2B shows the effects of the different treatment
combinations on plasma Bf concentrations. After 1 h, PT and
PT+Alb reduced plasma Bf concentrations with 35% (p,0.001 vs
controls) and 53% (p,0.001 vs controls), respectively. For the ET-
group, ET+PT-group and ET+PT+Alb-group the decrease in
plasma Bf concentrations was even more profound (280%, 280%
and 289% respectively; each p,0.001 vs controls, no statistically
significant difference between the three ET groups). Also, the
different ET-groups each showed significantly lower plasma Bf
concentrations compared to PT+Alb (p,0.05).
Plasma UCB Concentrations after 48 h
We also determined the long-term (48 h) hypobilirubinemic
effect of the different treatments. We compared treatment
combinations that are also used in the clinical practice: an ET
with or without the combination of PT or Alb administration.
Figure 3A shows the effects of the different treatment combina-
tions on plasma UCB concentrations after 48 h. In the ET-group
the plasma UCB concentrations returned back to physiological
Gunn rat values as described in the validation of the model.
ET+PT significantly reduced plasma UCB concentrations com-
pared to ET after 48 h (236%; p,0.05). Albumin further
potentiated this effect, shown in the significant decrease of
ET+PT+Alb compared to ET+PT (228%; p,0.05).
Plasma Bf Concentrations after 48 h
Figure 3B shows the effects of the different treatment
combinations on plasma Bf concentrations. After 48 h, the plasma
Bf concentrations of the ET was still significantly lower compared
to controls (248%; p,0.05 vs controls; data not shown). ET+PT
further reduced plasma Bf concentrations with 47% (NS, vs ET).
Albumin potentiated the decrease in plasma Bf concentrations
Figure 1. Course of plasma UCB and Bf concentrations after
exchange transfusion. Course of plasma UCB concentrations (A) and
plasma Bf concentrations (B) after sham transfusions (control) or an
exchange transfusion (ET) in Gunn rats. Rats were randomized to
receive sham transfusions (control) or an exchange transfusion (ET).
Values are mean6 SD. *p,0.01 compared to controls.#p,0.001 ET: T0
compared to T1.
doi:10.1371/journal.pone.0077179.g001
A Rat Model for Exchange Transfusion
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after 48 h, shown in a profound, significant decrease of
ET+PT+Alb compared to ET (281%; p,0.01).
Brain UCB Levels
Figure 4 shows that PT+Alb decreased brain bilirubin levels by
63% (p,0.001), compared with untreated controls. Adjunct
albumin thus lowered brain bilirubin levels by an additional
33% (NS), compared with phototherapy alone. ET+PT+Alb
decreased brain bilirubin levels by 61% (p,0.01), compared with
ET. Adjunct albumin thus lowered brain bilirubin levels by an
additional 57% (p,0.01), compared with ET+PT.
Discussion
In this study we successfully optimized ET during unconjugated
hyperbilirubinemia in a Gunn rat model. We also bring the
evidence that this Gunn rat-ET model might be very valuable to
evaluate the effect of modulating ET procedures and techniques,
and to compare its efficacy in combination with other treatments
to prevent brain damage during acute severe hyperbilirubinemia.
Our data indicate that ET is highly effective in decreasing UCB
and Bf within 1 h of treatment, and that combining ET with either
PT or PT+Alb does not further significantly potentiate this rapid
hypobilirubinemic effect. As follow up treatment after ET, the
combination of PT with Alb is most effective in maintaining this
hypobilirubinemic effect over 48 h.
Figure 2. Plasma UCB and Bf concentrations after 1 h. Acute
effects of sham transfusions (control) or phototherapy (PT), albumin
(Alb), an exchange transfusion (ET), or a combination of these on
plasma UCB concentrations (A) and plasma Bf concentrations (B) in
Gunn rats. Rats were randomized to receive sham transfusions (control)
or an exchange transfusion (ET), and were subsequently treated with
phototherapy (PT), albumin (Alb) or the combination of PT+Alb. Values
are mean 6 SD. *p,0.001 compared to controls. #p,0.05 compared
to PT. $p,0.05 compared to PT+Alb.
doi:10.1371/journal.pone.0077179.g002
Figure 3. Plasma UCB and Bf concentrations after 48 h. Long-
term effects of an exchange transfusion (ET), with or without the
combination of phototherapy (PT), or albumin (Alb), on plasma UCB
concentrations (A) and plasma Bf concentrations (B) in Gunn rats. Rats
were randomized to receive an exchange transfusion (ET), and were
subsequently treated with phototherapy (PT), albumin (Alb) or the
combination of PT+Alb. Values are mean 6 SD. *p,0.01 compared to
ET. #p,0.05 compared to ET+PT.
doi:10.1371/journal.pone.0077179.g003
A Rat Model for Exchange Transfusion
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Presently, ET is a very effective alternative treatment to PT in
severely jaundiced neonates. An ET is considered as a ‘‘rescue
treatment’’, if plasma UCB levels are severely elevated or fail to
respond to PT. Exchange transfusion generally reduces plasma
UCB concentrations by 50%, although the efficacy varies with the
severity of the ongoing hemolysis and the amount of bilirubin that
re-enters the circulation from the tissues [20]. This re-entry occurs
due to the diffusion of Bf from the tissue pool into the plasma pool
and decreases the risk of bilirubin-induced neurotoxicity [20].
Eventually, all therapy should aim to prevent neurotoxicity, and
this can only be achieved by decreasing (brain) tissue rather than
plasma UCB concentrations. Nevertheless, an ET has a consid-
erable morbidity, and even mortality has been reported [6–8].
Fortunately, the need for ETs has been greatly reduced since the
introduction of PT [21,22].
Our model makes it possible to determine if we can replace ET,
improve its efficacy and/or minimize its risks. An alternative
treatment option would be the administration of human serum
albumin (HSA). HSA-infusion can be used in combination with an
exchange transfusion in severely jaundiced neonates, when donor
blood is not immediately available [23], but this approach has
been disputed [23,24]. The rationale for HSA-infusion is that the
resultant increase in albumin concentration will enhance the
bilirubin/albumin-binding capacity in the intravascular compart-
ment, thereby promoting the mobilization of bilirubin from
extravascular tissues, including the central nervous system, into the
circulation. In this way albumin is used as an adjunct treatment in
order to more efficiently remove bilirubin [23].
Our experimental design on albumin administration differs to
clinical ET practices in humans with respect to dosage, timing,
and route of administration. In the clinics, albumin may be
administered to hyperbilirubinemic neonates, but its use seems
relatively rare. If administered, it has been advised to do so prior to
ET, aimed to increasing its efficacy by mobilizing bilirubin from
tissues. In the present study, we administered albumin immediately
after ET, aimed at preventing or mitigating a possible rebound of
Bf after ET. We administered albumin in a relatively high dosage
(2.5 g/kg, rather than ,1 g/kg in humans) via intraperitoneal
bolus injection, in contrast to i.v. infusion in humans. It should be
underlined that these methodological differences prevent direct
extrapolation of our present result towards the clinical situation.
Rather, present positive ‘‘proof of principle’’ results in our rat
model support the design of clinical studies in this direction.
Recently, we found that HSA enhances the efficacy of routine
PT in phototherapy-treated Gunn rats, both during permanent
and acute jaundice [11]. We speculated that HSA and PT work in
tandem: HSA binds bilirubin within the plasma, and PT then
promotes its excretion via the bile [11]. In this study we showed
that albumin administration in combination with either PT or ET
is already effective after 1 h of treatment. Furthermore, we showed
that the combination of PT+Alb is effective in decreasing plasma
UCB concentrations, plasma Bf concentrations and brain UCB
levels after 48 h. However, in this study we found that ET
decreases UCB and Bf concentrations even more than PT+Alb,
both in the acute and the chronic treatment situation. Our data
demonstrate that ET is still the most effective treatment option in
acute severe hyperbilirubinemia. Unfortunately, we were not able
to measure plasma albumin concentrations. Albumin is believed to
exert its beneficial effects in the blood circulation. In a previous
study in adult Gunn rats, we showed that HSA readily enters the
plasma compartment after i.p. injections [11]. It is worth
mentioning that in this previous study we have applied ‘‘albumin
only’’ treatment, i.e. without prior ET. ‘‘Albumin only’’ decreases
the plasma Bf with 54% after 48 hr [11]. The present results justify
a follow-up study on an ET+Alb-group. However, in the present
study-design we focused on the comparability of our animal-
experiments with the clinical situation. Next, it is worth
mentioning that in adult rats, PT may not be as efficient as in
rat pups. Both skin thickness and body mass/surface ratio are
increased in adults, thus underestimating the potential of PT
together with ET.
In our ET-model we chose a venovenous exchange via one
jugular vein in 20 minutes. Various models for exchange of blood
are described, each for different purposes. Eguchi et al. performed
a total blood exchange in rats, and showed that total blood
exchange suppressed the early stage of liver regeneration following
partial hepatectomy [25]. These scientists performed the total
blood exchange via the right femoral vein and artery. Henry et al.
improved monoclonal antibody tumor/background ratios with
ETs in rats [26]. They used the right common carotid artery for
the blood exchange. Takeda et al. studied the effect of blood ET as
an initial treatment of acute hemorrhagic pancreatitis in rats [27].
Blood ET was performed via a previously indwelt tube in the
inferior vena cava. Hodges et al. studied the effect of an ET on the
efficacy of penicillin therapy of pneumococcal infection in rats
[28]. The left external jugular vein was used to perform the ET.
We based our model to a certain extent on the latter approach.
Kurantsin-Mills et al. studied flow dynamics of human sickle
erythrocytes in the mesenteric microcirculation of rats that
underwent an ET via the femoral vein [29]. The time schedule
we used for infusion and blood outflow was partly based on this
study. Since we had a different goal than the studies described
above, namely exchange of hyperbilirubinemic blood, we decided
to develop our own model.
We used fresh donor-rat blood, collected at the same day as the
ET takes place. The life span of erythrocytes is approximately 120
days in human adults, 90 days in neonates, and 50–60 days in rats
[30]. However, the storage time of red blood cells for rats is much
shorter than for human red blood cells, maximum 7 days
compared to maximum 30 days respectively [31]. Hemolysis of
rat red blood cells happens quickly, and after 7 days all the red
blood cells are lysed [31].
Figure 4. Brain bilirubin levels. Effects of sham transfusion
(controls), phototherapy (PT), albumin (Alb), an exchange transfusion
(ET) or a combination ofn these on brain bilirubin levels in Gunn rats.
For experimental setup, kindly refer to the Methods section. Values are
mean 6 SD. *p,0.05 compared to controls. #p,0.01 compared to PT.
$p,0.05 compared to ET and ET+PT.
doi:10.1371/journal.pone.0077179.g004
A Rat Model for Exchange Transfusion
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In conlusion, we successfully optimized and verified an animal
model for ET for treatment of severe unconjugated hyperbiliru-
binemia. Our data indicate that ET is a more effective treatment
option for acute hyperbilirubinemia, than either PT or the
combination of PT and Alb. The combination of PT and Alb was
the most effective follow up treatment after ET for long term
(48 h) hypobilirubinemic effect. The availability of this optimized
model could be very helpful to further optimize the treatment for
acute, potentially neutotoxic hyperbilirubinemia.
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